Literature DB >> 2324790

Prescription-event monitoring: methodology and recent progress.

N S Rawson1, G L Pearce, W H Inman.   

Abstract

Event monitoring was first suggested 25 years ago as a way of detecting adverse reactions to drugs. Prescription-event monitoring (PEM), which has been developed by the Drug Safety Research Unit, is the first large-scale systematic post-marketing surveillance method to use event monitoring in the U.K. PEM identifies patients, who have been prescribed a particular drug, and their doctors from photocopies of National Health Service prescriptions which are processed centrally in England. A personalized follow-up questionnaire ("green form") is mailed to each patient's general practitioner, usually on the first anniversary of the initial prescription, asking for information about the patient, especially any "events" that he or she may have experienced since beginning treatment with the drug. The methodology of PEM is presented, together with examples of analyses that can be performed using results from recent studies. The problems and benefits of PEM are discussed.

Entities:  

Mesh:

Year:  1990        PMID: 2324790     DOI: 10.1016/0895-4356(90)90140-k

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  9 in total

Review 1.  Measuring the frequency of adverse drug reactions.

Authors:  P C Waller
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

2.  ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in prescription-event monitoring.

Authors:  K Kubota; N Kubota; G L Pearce; W H Inman
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

3.  Terminology in prescription-event monitoring.

Authors:  K Kubota; W H Inman
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

4.  Patterns of respiratory drug use in the Lombardy region of Italy, 1995-1997.

Authors:  Ferdinando E Vegni; Paul Wilkinson
Journal:  Eur J Epidemiol       Date:  2006-07-21       Impact factor: 8.082

5.  Systematic review and guide to selection of selective serotonin reuptake inhibitors.

Authors:  J G Edwards; I Anderson
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

6.  Post-marketing studies: the work of the Drug Safety Research Unit.

Authors:  F J Mackay
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

7.  A need to intensify drug surveillance in Germany.

Authors:  J F Kapp; R Zentgraf; A Widmer; E Schöpf
Journal:  Klin Wochenschr       Date:  1991-10-31

8.  Vasodilation-related adverse events in diltiazem and dihydropyridine calcium antagonists studied by prescription-event monitoring.

Authors:  K Kubota; G L Pearce; W H Inman
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  A system for reporting and evaluating adverse drug reactions of herbal medicine in Taiwan from 1998 to 2016.

Authors:  Hen-Hong Chang; Su-Yin Chiang; Pei-Chun Chen; Chia-Han Tsai; Rong-Chi Yang; Chiu-Lin Tsai; Tsung-Hsiu Wu; Yow-Wen Hsieh; Yu-Chun Lin; Yung-Te Kuo; Kuan-Chung Chen; Hsueh-Ting Chu
Journal:  Sci Rep       Date:  2021-11-02       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.